Drug Profile
Trastuzumab conjugate - BioIntegrator
Alternative Names: BI-CON-02Latest Information Update: 03 Aug 2022
Price :
$50
*
At a glance
- Originator BioIntegrator
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Breast cancer
Most Recent Events
- 03 Aug 2022 Trastuzumab conjugate is still in phase I trials for Breast-cancer (Metastatic disease, Second-line therapy or greater) in Russia (IV, Infusion) (BioIntegrator pipeline, August 2022).
- 28 Feb 2022 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease, Second-line therapy or greater) in Russia (IV, Infusion)
- 14 Jul 2019 Biointegrator terminates phase-I trial in Breast cancer (Metastatic disease, Second-line therapy or greater) in Russia (IV) (NCT03062007)